You know why that Novartis a possibility?
https://www.************.com/special-reports/top-20-pharma-companies-2021-revenue#:~:text=Anti%2Dinflammation%20biologic%20Cosentyx%20and,billion%20and%20%243.55%20billion%2C%20respectively.
type fiercepharma
Why does it make sense? The MoA behind Rexlemestrocel will complement that behind Entrestro, and the company will be able to have a huge presence in the market for heart failure. Entrestro is already top-selling.
Ann: CEO Presentation to 2023 Annual General Meeting, page-44
-
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |